Zacks Investment Research Upgrades Cryolife (CRY) to Hold
Cryolife (NYSE:CRY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday.
According to Zacks, “CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries. It operates throughout the U.S. and internationally. CryoLife manufactures and distributes BioGlue Surgical Adhesive, an FDA-approved adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in Europe for use in soft tissue repair and has received additional marketing approvals in several other countries throughout the world. CryoLife’s BioFoam Surgical Matrix is CE marked in Europe for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical. CryoLife distributes PerClot, a powdered hemostat, in Europe and other select international countries. “
CRY has been the subject of several other research reports. TheStreet cut shares of Cryolife from a “b” rating to a “c+” rating in a research report on Monday, October 30th. Northland Securities reiterated a “buy” rating and set a $23.50 target price on shares of Cryolife in a research report on Monday, November 13th. Canaccord Genuity reiterated a “buy” rating and set a $25.00 target price on shares of Cryolife in a research report on Wednesday, January 3rd. Finally, Lake Street Capital upped their target price on shares of Cryolife to $26.00 and gave the company a “buy” rating in a research report on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Cryolife currently has a consensus rating of “Buy” and a consensus target price of $23.63.
Cryolife (NYSE:CRY) last posted its quarterly earnings data on Monday, October 30th. The medical equipment provider reported $0.08 earnings per share for the quarter, hitting the consensus estimate of $0.08. Cryolife had a net margin of 5.28% and a return on equity of 6.43%. The firm had revenue of $44.00 million during the quarter, compared to analysts’ expectations of $44.60 million. During the same quarter in the previous year, the company posted $0.13 EPS. Cryolife’s revenue was down 2.9% on a year-over-year basis. equities research analysts anticipate that Cryolife will post 0.28 earnings per share for the current year.
In other Cryolife news, CAO Amy Horton sold 4,000 shares of the company’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total transaction of $76,000.00. Following the completion of the sale, the chief accounting officer now owns 98,705 shares in the company, valued at approximately $1,875,395. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO David Ashley Lee sold 33,190 shares of the company’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total transaction of $630,610.00. Following the sale, the chief financial officer now owns 324,339 shares of the company’s stock, valued at approximately $6,162,441. The disclosure for this sale can be found here. Insiders have sold a total of 59,190 shares of company stock valued at $1,138,240 in the last quarter. Corporate insiders own 6.00% of the company’s stock.
Several institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. increased its position in shares of Cryolife by 21.0% in the 3rd quarter. Principal Financial Group Inc. now owns 258,323 shares of the medical equipment provider’s stock valued at $5,864,000 after buying an additional 44,777 shares in the last quarter. Prudential Financial Inc. increased its position in shares of Cryolife by 51.6% in the 3rd quarter. Prudential Financial Inc. now owns 133,863 shares of the medical equipment provider’s stock valued at $3,039,000 after buying an additional 45,580 shares in the last quarter. Hartford Investment Management Co. bought a new stake in shares of Cryolife in the 3rd quarter valued at $276,000. Rhumbline Advisers increased its position in shares of Cryolife by 9.3% in the 3rd quarter. Rhumbline Advisers now owns 62,599 shares of the medical equipment provider’s stock valued at $1,421,000 after buying an additional 5,308 shares in the last quarter. Finally, KBC Group NV increased its position in shares of Cryolife by 63.0% in the 3rd quarter. KBC Group NV now owns 13,447 shares of the medical equipment provider’s stock valued at $305,000 after buying an additional 5,197 shares in the last quarter. Institutional investors own 73.28% of the company’s stock.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.